Addex Therapeutics Ltd · SIX:ADXN
Addex Therapeutics — Investor Presentation (October 2026)
46 slides from Addex Therapeutics's investor presentation, October 2026
Slide 1: Innovative Treatments for Central Nervous System Disorders
Innovative Treatments for Central Nervous System Disorders October 2026 Allosteric modulators for human health
Slide 2: Disclaimer
Disclaimer These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their di
Slide 3: Addex Overview
Addex Overview GABAB PAM for cough ready to enter IND enabling studies GABAB PAM for SUD2 - IND enabling studies successfully completed – ready to High value start Phase 1 programs reaching Dipraglurant for post-stroke/TBI1 recovery – Phase 2 ready significant milestones Neurosterix portfoli
Slide 4: Pipeline of In House Discovered Programs
Pipeline of In House Discovered Programs Molecule / Stage Milestone Partner MoA Discovery IND Studies Phase 1 Phase 2a Dipraglurant Ready to start Phase 2a Brain injury recovery - post-stroke / TBI (mGlu5 NAM) study* ADX71149 Indication under evaluation New indication selection (mGlu2 PAM) GABAB PAM
Slide 5: Dipraglurant (mGlu5 NAM) for Brain Injury Recovery Post-Stroke / TBI
Dipraglurant (mGlu5 NAM) for Brain Injury Recovery Post-Stroke / TBI Targeting neuroplasticity early in rehabilitation to promote rebuilding of neuronal connections and sensorimotor recovery 5
Slide 6: Post Stroke / TBI Recovery - Unmet Medical Need & Commercial Opportunity
Post Stroke / TBI Recovery - Unmet Medical Need & Commercial Opportunity Many stroke /TBI patients suffer motor >101 million ischemic stroke and somatosensory impairment survivors worldwide1 Potential chronic disability & >12 million new strokes/yr low quality of life (1 every 3 seconds)1 Di
Slide 7: mGlu5: An Innovative Target for Brain Injury Recovery
mGlu5: An Innovative Target for Brain Injury Recovery Healthy brain mGlu5 NAM supports rebuilding of neuronal connections (b) Recovery + mGlu5 NAM (a) mGlu5 brain Good inter & intra- distribution nodal connectivity mGlu5 Lesion effects: mGlu5 NAM promotes synaptic Densely expressed in the brain
Slide 8: Preclinical Data: mGlu5 Inhibition Promotes Post-Stroke Recovery
Preclinical Data: mGlu5 Inhibition Promotes Post-Stroke Recovery MTEP treatment resulted in a significant Dipraglurant significantly restored functional recovery of functional control control in a one-week experiment Dipraglurant enhanced functional brain recovery in a rat model of experimental stro
Slide 9: MRI Imaging Data: Post-Stroke Resting State Functional Connectivity
MRI Imaging Data: Post-Stroke Resting State Functional Connectivity Intrahemispheric Connectivity Interhemispheric Connectivity mGlu5 inhibitors promote intra- and inter-hemispheric connectivity following stroke https://doi.org/10.1093/brain/awad293 9
Slide 10: Dipraglurant for Post-Stroke/TBI Recovery - Development Status
Dipraglurant for Post-Stroke/TBI Recovery - Development Status Fast onset of action and short half-life - Ideally suited for concurrent dosing with rehabilitation Extensively profiled Phase 1 studies - 5 studies with >100 patients - Including receptor occupancy (PET ligand study) Phase 2 studi
Slide 11: GABAB PAM Platform – Going Beyond Baclofen
GABAB PAM Platform – Going Beyond Baclofen GABA B PAM PLATFORM Substance abuse Multiple back ups with potential Indication Chronic cough disorders for other indications Stage IND studies completed Preclinical Preclinical Next IND enabling studies ready to File IND & start Phase 1 Clinical candidate
Slide 12: GABAB PAM for Substance Use Disorders
GABAB PAM for Substance Use Disorders Going beyond baclofen to treat substance use disorders with improved safety and tolerability 12
Slide 13: SUD - Unmet Medical Need and Commercial Opportunity
SUD - Unmet Medical Need and Commercial Opportunity SUD (opioid, alcohol, cocaine) High unmet medical need – Uncontrolled use of a substance ‒ SUD: 16.8% of US population despite harmful consequences ‒ AUD – 9.7% – Development of tolerance and ‒ Near 90% untreated withdrawal ‒ High rates of rela
Slide 14: GABAB PAM for Substance Use Disorder
GABAB PAM for Substance Use Disorder Baclofen (GABAB agonist) used off label for alcohol use disorder ADX71441 attenuates alcohol self-administration and relapse to alcohol Clinically validated MoA seeking in rats3 and alcohol consumption in mice4 ADX71441 reduces cocaine self-administration i
Slide 15: GABAB PAM for Chronic Cough
GABAB PAM for Chronic Cough Going beyond baclofen to treat cough with improved safety and tolerability 15
Slide 16: Cough - Unmet Medical Need and Commercial Opportunity
Cough - Unmet Medical Need and Commercial Opportunity Chronic cough 10% in the general population – Lasting > 8 weeks1 Persists >1 year in 60% of – >700 coughs/day patients Multiple comorbidities Disease Prevalence Market 1.45B 2 Standard of Competition Care P2X3 Inhibitors (Phase 3): Ine
Slide 17: Pharmacological Treatment of Chronic Cough – Efficacy vs Tolerability
Pharmacological Treatment of Chronic Cough – Efficacy vs Tolerability GABAB Dextro- Nalbuphine Gabapentin & Agonist Addex Use / side-effects metorphan Opioids (Phase 2) pregabalin Amitriptyline P2X3* Baclofen PAM Treatment type Chronic Acute ? Acute Acute Chronic Chronic+ Chronic Risk of Abuse Yes Y
Slide 18: GABAB Receptor - Validated Target in Cough
GABAB Receptor - Validated Target in Cough GABAB receptor – Expressed throughout the cough neural circuit – Activation reduces neuronal excitability – Potential for broad application in cough patients Baclofen, an orthosteric agonist – Used off-label in patients with chronic cough – Clinical stu
Slide 19: GABAB PAM for Cough – Program Status
GABAB PAM for Cough – Program Status Addex has a range of diverse potent and selective GABAB PAMs that were explored for cough indications Clinical candidate selected: – Favorable developability – Pre-IND activities completed – CMC completed In vivo proof-of-concept in a broad range of cough m
Slide 20: Citric Acid Cough in Guinea Pigs - Total number of coughs
Citric Acid Cough in Guinea Pigs - Total number of coughs Compound A results in a dose-dependent reduction in number of coughs (MED 1 mg/kg) Compound A reaches maximal effects that are equal or higher than with reference compounds 20
Slide 21: Citric Acid Cough in Guinea Pigs – Latency to 1st Cough
Citric Acid Cough in Guinea Pigs – Latency to 1st Cough Compound A results in a dose-dependent increase in cough latency Compound A reaches maximal delays in the onset of cough that are similar or better than reference compounds, except codeine 21
Slide 22: Citric Acid Cough in Guinea Pigs – Respiratory Rate
Citric Acid Cough in Guinea Pigs – Respiratory Rate Biomarker of sedation Compound A had no effect on respiratory rate at up to 60 mg/kg, while other compounds resulted in marked reduction in respiratory rate at their highest doses 22
Slide 23: Citric Acid Cough in Guinea Pigs
Citric Acid Cough in Guinea Pigs Cough frequency Latency to 1st cough Compound ED50 Max Max Compound Max Max (mg/kg) Efficacy Efficacy* Efficacy Efficacy* Compound A 5.96 70% 70% Compound A 282 282% Nalbuphine 7.57 70% 65% Nalbuphine 182 100% Orvepitant 14.2 55% 51% Orvepitant 240 235% Baclofen 0.93
Slide 24: Citric Acid Cough in Guinea Pigs: Pharmacokinetic/pharmacodynamic interaction
Citric Acid Cough in Guinea Pigs Growth hormone in plasma % Reduction in resp. rate Pharmacokinetic/pharmacodynamic interaction % Reduction in BT % Reduction in resp. rate Reduction in BT Growth hormone in plasma Antitussive activity of Compound A shows good PK/PD and correlation between tussive rea
Slide 25: Citric Acid Cough in Guinea Pigs – Reduction in Body Temperature
Citric Acid Cough in Guinea Pigs – Reduction in Body Temperature Rodent biomarker of GABAB receptor occupancy in the CNS Compound A resulted in a minor (0.7°C) reduction in body temperature only at the highest dose (60 mg/kg), in contract to near 2°C seen with baclofen at 3 mg/kg. Compound A i
Slide 26: Citric Acid Cough in Guinea Pigs – Growth Hormone in Plasma
Citric Acid Cough in Guinea Pigs – Growth Hormone in Plasma Biomarker of GABAB receptor occupancy in the CNS Compound A did not increase growth hormone in plasma at up to 60 mg/kg, while baclofen caused more than 2x increases in growth hormone concentration Compound A is likely to have less CN
Slide 27: ATP Potentiated Citric Acid Cough in Guinea Pigs
ATP Potentiated Citric Acid Cough in Guinea Pigs Compound A appears more Total number of coughs Cough latency potent than P2X3 inhibitor in the ATP – CA cough In a follow-up experiment involving co-administration of Compound A and P2X3 inhibitor isobolographic analysis revealed potentiation effe
Slide 28: ATP Potentiated Citric Acid Cough in Guinea Pigs
ATP Potentiated Citric Acid Cough in Guinea Pigs Both Compound A and P2X3 have no effect on respiratory rate, BT and growth hormone at up to 30 mg/kg Tolerability profile of Compound A is similar to that of P2X3 inhibitor, but without any taste-related side- effects 28
Slide 29: Citric Acid Cough in Guinea Pigs
Citric Acid Cough in Guinea Pigs Following sub-chronic treatment there were no signs of reduced potency or efficacy There were no marked changes in the respiratory rate, body temperature and growth hormone release in animals given Compound A acutely or sub-chronically Compound A (mg/kg) 29
Slide 30: Activity of Compound A in a Model of CA Induced Cough: Sub-chronic Treatment
Activity of Compound A in a Model of CA Induced Cough in Guinea Pigs: Sub-chronic Treatment SIDE EFFECTS-RELATED READOUTS Compound A (mg/kg) Compound A (mg/kg) Compound A (mg/kg) No marked changes in side effect related readouts following sub-chronic administration 30
Slide 31: Bleomycin Model of IPF Related Exacerbated Cough in Guinea Pigs
Bleomycin Model of IPF Related Exacerbated Cough in Guinea Pigs Acute Bleomycin (BLM) (8 U/kg, 100 µL volume) Oropharyngeal dosing CA (0.1 M) CA (0.1 M) CA (0.1 M) CA (0.1 M) Vehicle (1% CMC) p.o. (QD, Days 0-28) 10 mg/kg Cpd A, p.o. (QD, Days 0-28) Intact 0 7 14 21 28 (Days) Groups Culled on day 7
Slide 32: BLM IPF Model - Effects of Compound A on Cough Frequency
BLM IPF Model - Effects of Compound A on Cough Frequency Chronic administration of Compound A resulted in a robust and consistent reduction in BLM- stimulated cough frequency up to the last day of testing on Day 28 32
Slide 33: BLM IPF Model - Effects of Compound A on Cough Latency
BLM IPF Model - Effects of Compound A on Cough Latency Chronic administration of Compound A resulted in a full reversal of BLM-mediated short latencies to the level of untreated controls between days 14 and 28 33
Slide 34: BLM IPF Model - Effects of Compound A on Reduction in Body Temperature
BLM IPF Model - Effects of Compound A on Reduction in Body Temperature BACLOFEN A minimal (-0.4 to -0.7 °C) reduction in body temperature in response to Compound A treatment is indicative of low-moderate central receptor engagement Marked (- 2°C) reduction in body temperature was seen with baclo
Slide 35: BLM IPF Model - Effects of Compound A on Respiratory Rate
BLM IPF Model - Effects of Compound A on Respiratory Rate BACLOFEN COMPOUND A Chronic administration of Compound A had no marked impact on the respiratory rate up to Day 28 Baclofen resulted in marked reduction in respiratory rate at >3 mg/kg 35
Slide 36: BLM IPF Model: Guinea Pig Lung Histopathology Analysis (Day 7)
BLM IPF Model: Guinea Pig Lung Histopathology Analysis (Day 7) Groups Intact BLM – BLM – Criteria controls Vehicle Cpd A INTACT Ashcroft 2.8 1.7 1.2 score % of 13 11.7 6.7 affected lung vehicle BLM – Final score 42 20.8 10 Sub-chronic administration of Compound A was associated with Cpd A BLM – ma
Slide 37: BLM IPF Model: Guinea Pig Lung Histopathology Analysis (Day 28)
BLM IPF Model: Guinea Pig Lung Histopathology Analysis (Day 28) Groups Intact BLM – BLM – INTACT Criteria controls Vehicle Cpd A Ashcroft 1.5 2.1 1.4 score % of 9.2 11.3 6.3 affected lung Final score 17.5 36.9 10 vehicle Chronic administration of BLM – Compound A was associated with markedly lower
Slide 38: BLM IPF Model: Conclusions
BLM IPF Model: Conclusions Chronic QD administration of Compound A in BLM-exposed animals: – Marked and sustained antitussive effects in cough frequency and latency – Lower Ashcroft scores and percentage of affected lung in comparison to BLM exposed animals at Day 7 and Day 28 – No effects on immu
Slide 39: Effect of Compound A in Citric Acid Induced Cough in NHP & Guinea Pigs
Effect of Compound A in Citric Acid Induced Cough in NHP & Guinea Pigs NHP Guinea Pigs Compound A i.v. administration (mg/kg) p.o. administration Compound A showed significant efficacy (63-69% reduction) with p<0.001 in the total number of coughs at 2 mg/kg - equivalent to that shown in guinea pig
Slide 40: Top-Level Plan for GABAB PAM in Cough
Top-Level Plan for GABAB PAM in Cough Clinical candidate selected – Reproducible efficacy with good PK/PD in guinea pigs (MED 1 mg/kg) – Different TPP available - potential for broad application in cough patients – Favourable developability and non-GLP tox studies completed in Rat, NHP & Dog – Met
Slide 41: 20% Equity Interest in Neurosterix
20% Equity Interest in Neurosterix Well funded preclinical portfolio of high value assets 41
Slide 42: Neurosterix
Neurosterix Addex spin-out company – Series A funding of $65 million in 2024 led by Perceptive Advisors – Addex contributed allosteric modulator drug discovery platform and portfolio of preclinical programs – Addex received CHF5 million and a 20% equity interest High value pipeline advancing to
Slide 43: Addex Financials and Stock
Addex Financials and Stock 43
Slide 44: Financials and Stock
Financials and Stock Cash at June 30, 2026: CHF0.8M 203.5 M outstanding shares (USD1.0M) – Armistice Capital LLC – 19.57%* – CHF2.8M raised in August – Cash runway through Q4 2027 218.65M shares incl. treasury shares (285.19M fully diluted) No debt – Management & board holds – 11.99%* Trad
Slide 45: Summary
Summary 20% equity interest in Neurosterix (backed by Perceptive Advisors) Multiple high value Investment in Stalicla, clinical stage precision medicine neurodevelopmental partnerships disorder company Dipraglurant - brain injury recovery Phase 2a ready to start GABAB PAM for chronic cough r
Slide 46: Allosteric Modulators for Human Health
ALLOSTERIC MODULATORS FOR HUMAN HEALTH www.addextherapeutics.com
Addex Therapeutics — Investor Presentation (October 2026) on 6ix